Rep. Robert Bresnahan, Jr. Sells Off Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of West Pharmaceutical Services, Inc. NYSE: WST. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.

West Pharmaceutical Services Stock Down 0.6 %

Shares of NYSE WST traded down $1.35 during trading hours on Friday, hitting $213.39. The company had a trading volume of 563,300 shares, compared to its average volume of 728,337. The stock has a market capitalization of $15.33 billion, a P/E ratio of 31.90, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $372.52. The firm's 50 day moving average is $216.55 and its 200-day moving average is $278.41. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.23. The company had revenue of $698.00 million for the quarter, compared to analyst estimates of $685.24 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. West Pharmaceutical Services's revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 6th. Investors of record on Wednesday, July 30th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio is currently 13.19%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Stephens raised West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, April 21st. KeyCorp reduced their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Evercore ISI assumed coverage on shares of West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $275.00 price target on the stock. StockNews.com downgraded shares of West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 target price on the stock in a research report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $332.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC grew its position in West Pharmaceutical Services by 5.4% during the 4th quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier's stock worth $205,000 after acquiring an additional 32 shares during the last quarter. Baron Wealth Management LLC grew its holdings in shares of West Pharmaceutical Services by 1.9% during the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier's stock worth $631,000 after purchasing an additional 35 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of West Pharmaceutical Services by 18.9% in the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier's stock valued at $78,000 after buying an additional 38 shares during the period. Lake Street Advisors Group LLC boosted its position in West Pharmaceutical Services by 5.8% during the 4th quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier's stock worth $233,000 after buying an additional 39 shares during the period. Finally, Cornerstone Planning Group LLC raised its stake in shares of West Pharmaceutical Services by 57.1% during the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.